| Name | Title | Contact Details |
|---|
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are
DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,
#Healthcare needs to get simpler to get better. To achieve this, we focus on the #patientexperience and develop more effective #medicaldevices. #breastcancer
Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.